Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole aims to improve known therapeutic proteins, cytokine drugs through chimeras
BioCentury | Apr 14, 2014
Clinical News

Ampligen rintatolimod: Additional Phase III data

BioCentury | Jan 6, 2014
Clinical News

Ampligen rintatolimod: Phase II started

BioCentury | May 7, 2012
Clinical News

Ampligen rintatolimod: Phase I/II started

BioCentury | Aug 29, 2011
Clinical News

Ampligen rintatolimod: Phase I/II started

BioCentury | Jun 27, 2011
Clinical News

Ampligen rintatolimod: Phase I/II started

BioCentury | Dec 6, 2010
Clinical News

Ampligen rintatolimod: Additional Phase III data

Items per page:
1 - 7 of 7